Connect with us

Technology

From Insight to Impact: TruDoc Acquires Wellthy Therapeutics to Deliver Premier Digital Health Services in the GCC and Expand to India

Published

on

MUMBAI, India and DUBAI, UAE, Feb. 13, 2024 /PRNewswire/ — In a landmark move that promises to transform digital healthcare, TruDoc Healthcare, the GCC’s premier virtual primary care provider, is thrilled to announce its acquisition of Wellthy Therapeutics. Wellthy Therapeutics, Asia’s leading clinically validated chronic disease management platform, joins forces with TruDoc, creating new standards in healthcare outcome, quality & patient experience in the region, and heralds TruDoc’s strategic expansion into new markets, including India.

The acquisition of Wellthy Therapeutics’ advanced behavioral science and digital therapeutic solutions with TruDoc’s extensive virtual and in-home healthcare services marks the dawn of a transformative healthcare era. This integration ensures round-the-clock access to high-quality care, tailored treatment plans, and innovative care delivery methods for patients. These advancements hold the potential to greatly enhance health results and streamline healthcare expenditures.

The combined vision is rooted in patient-centric care, aiming to deliver a seamless, integrated healthcare experience that places the patient at the heart of every decision. With TruDoc’s leadership in the GCC and Wellthy’s proven track record in Asia, this alliance is poised to reinforce TruDoc’s leading position in the region as a tech-enabled primary care provider.

Sharing his perspective on the acquisitions, Vish Narain, Chairman of TruDoc, stated, “With this acquisition, we’re hitting a key milestone on our path to transforming healthcare across the GCC and beyond. We are crafting an integrated care experience that’s tailored to the changing needs of our patients and our clients. We envision a future where primary care is easily accessible, starting with digital platforms, followed by in-home care, with in-clinic visits only when needed.”

“Our founding goal at Wellthy was ambitious, to impact millions of lives. This partnership accelerates our progress towards our impact goal, broadening our reach while enhancing patient outcomes,” stated Abhishek Shah, Founder of Wellthy Therapeutics. “The combined capabilities are uniquely positioned to significantly lower healthcare expenses, contribute to savings, and reduce unnecessary hospital and clinic visits, while substantially improving the patient experience.”

The synergy of TruDoc and Wellthy Therapeutics will enable insurers, employers, and governments to provide high-quality, individualized care. Integrated services offer connected care, remote monitoring, and instant access to healthcare professionals, all supported by AI and personalized care protocols. This approach not only elevates patient care but also delivers validated results in terms of cost reductions across the outpatient care spectrum.

In pursuit of Vision 2025, TruDoc and Wellthy Therapeutics are aligning their clinical strengths and digital health expertise to create a sustainable healthcare ecosystem aimed at impacting 10 million lives. This strategic partnership signifies a significant step towards closing the loop on full stack primary care, leveraging TruDoc’s clinical proficiency and Wellthy Therapeutics’ prowess in digital health and behavioral science.

About TruDoc Healthcare

TruDoc Healthcare, the GCC’s leading telehealth and virtual care provider, offers a ‘virtual first’ approach to healthcare delivery, ensuring high-quality, accessible services. With round-the-clock expert consultations, evidence-based care, and centralized medical records, TruDoc prioritizes patient needs while leveraging state-of-the-art technology. Whether delivered virtually, in-home, or in-clinic as necessary, TruDoc focuses on accessibility, quality, and cost-effectiveness, reshaping healthcare delivery and promoting overall well-being.

For more details please visit: www.trudocgroup.com

About Wellthy Therapeutics

Wellthy Therapeutics is Asia’s leading virtual chronic disease management company. Wellthy’s solutions combine behavioral science and technology to deliver personalized digital therapies. Since 2015, Wellthy has delivered solutions across >15 chronic conditions, impacting hundreds of thousands of patients, while working deeply with health insurers and life science companies in multiple countries to lower the cost of care and improve population outcomes.

For more details please visit: www.wellthytherapeutics.com

For deeper insights into this groundbreaking acquisition or to learn more about how we are unlocking the future of healthcare, we are just an email away:
marketing@wellthy.care 

Logo: https://mma.prnewswire.com/media/2074722/4030859/Wellthy_Therapeutics_Logo.jpg 

 

View original content:https://www.prnewswire.com/in/news-releases/from-insight-to-impact-trudoc-acquires-wellthy-therapeutics-to-deliver-premier-digital-health-services-in-the-gcc-and-expand-to-india-302060283.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MATSON ANNOUNCES ADDITION OF 3 MILLION SHARES TO EXISTING SHARE REPURCHASE PROGRAM AND QUARTERLY DIVIDEND OF $0.36 PER SHARE

Published

on

By

HONOLULU, April 23, 2026 /PRNewswire/ — The Board of Directors of Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, approved adding three million shares to its existing share repurchase program and extending the program to December 31, 2029.  As of April 23, 2026, the existing share repurchase program had approximately 0.7 million shares remaining.  The Board also declared a second quarter dividend of $0.36 per common share.  The dividend will be paid on June 4, 2026 to all shareholders of record as of the close of business on May 7, 2026.

“We are pleased to announce an additional three million shares to our existing share repurchase program,” said Matt Cox, Matson’s Chairman and Chief Executive Officer.  “Since we commenced our share repurchase program in August 2021, we have repurchased approximately 14.3 million shares, or approximately 33% of the then outstanding shares, for a total cost of $1.3 billion.  Going forward, we will continue to be both disciplined and opportunistic in our capital allocation, and we remain committed to returning excess cash to shareholders to create additional shareholder value over the long-term.” 

Shares will be repurchased in the open market from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common shares and general market conditions.  The Company may enter into Rule 10b5-1 plans to facilitate purchases under the program.  The repurchase program may be suspended or discontinued at any time.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services.  Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia.  Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia.  The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges.  Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia.  Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska.  Additional information about the Company is available at www.matson.com.

Forward Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, statements about capital allocation plans, the timing, manner and volume of repurchases of common shares pursuant to the repurchase program, and use of excess cash.  These forward-looking statements are not guarantees of future performance.  This release should be read in conjunction with our Annual Report on Form 10-K and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release.  We do not undertake any obligation to update our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-addition-of-3-million-shares-to-existing-share-repurchase-program-and-quarterly-dividend-of-0-36-per-share-302752377.html

SOURCE Matson, Inc.

Continue Reading

Technology

Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards

Published

on

By

ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients across multiple states, has been named a finalist in the MMIT Patient Choice Awards, a recognition based on patient-reported satisfaction and experience.

Accord was selected as the only independent pharmacy among finalists in its category, alongside national pharmacy organizations such as Walgreens Specialty Pharmacy and Walmart Specialty Pharmacy. This distinction highlights the company’s commitment to delivering personalized, high-touch care for patients managing complex and chronic conditions.

The MMIT Patient Choice Awards recognize specialty pharmacies that demonstrate excellence in patient satisfaction, service quality, and overall care experience. Finalists are determined based on direct patient feedback, making the recognition a meaningful reflection of the trust patients place in their pharmacy providers.

“Being recognized alongside national organizations and as the only independent finalist validates our belief that personalized, patient-centered care drives better outcomes. We are building a model that combines clinical depth, national reach, and operational flexibility to better serve patients, providers, and partners.” said AJ Patel, Founder and Pharmacy Manager of Accord Specialty Pharmacy.

Accord Specialty Pharmacy supports patients across complex specialty categories, including oncology, rare disease, and infusion, through a clinically driven, high-touch care model designed to improve access, adherence, and outcomes. The company’s approach emphasizes personalized support, responsive care coordination, and strong clinical engagement to help patients navigate complex therapies more effectively. With a growing national footprint and multi-state licensure, Accord is positioned to support patients, providers, and partners across diverse markets.

For more information, visit MMIT Announces Finalists of the 11th Specialty Pharmacy Patient Choice Awards – MMITNetwork.

About Accord Specialty Pharmacy:

Accord Specialty Pharmacy is an ACHC-accredited, multi-state licensed independent specialty pharmacy located in Central Florida, dedicated to delivering high-quality, patient-centered care for individuals managing complex and chronic conditions. Through personalized support, clinical expertise, and a high-touch approach, Accord helps patients navigate every step of their treatment journey. Learn more at www.accordspecialty.com.

CONTACT: contact@accordspecialty.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-specialty-pharmacy-named-finalist-in-mmits-11th-annual-retail-specialty-pharmacy-patient-choice-awards-302752327.html

SOURCE Accord Specialty

Continue Reading

Technology

HAIVISION ANNOUNCES VOTING RESULTS FROM 2026 ANNUAL MEETING OF SHAREHOLDERS

Published

on

By

MONTRÉAL, April 23, 2026 /CNW/ – Haivision Systems Inc. (“Haivision” or the “Company”) (TSX: HAI) is pleased to announce the voting results from its annual meeting of shareholders held today in a virtual format.

A total of approximately 45.97 % of the issued and outstanding common shares of Haivision were represented at the meeting.

Election of Directors

Each of the six nominated directors of Haivision was elected as director of the Company with the following results:

Director

Votes
For

% Votes
For

Votes
Against

% Votes
Against

Miroslav Wicha

11,110,245

99.26 %

82,583

0.74 %

Harvey Bienenstock

11,155,137

99.66 %

37,691

0.34 %

Robin M. Rush

11,121,855

99.37 %

70,973

0.63 %

Neil Hindle

10,794,005

96.44 %

398,823

3.56 %

Julie Tremblay

10,941,969

97.76 %

250,859

2.24 %

Lee K. Levy II

9,084,418

81.16 %

2,108,410

18.84 %

2.   Appointment of Auditors

Deloitte LLP were reappointed auditors of the Company for the ensuing year with 12,492,582 (98.84%) votes cast in favour and 146,406 (1.16%) votes withheld.

3.   Approval of the Unallocated Awards under the Company’s Equity Incentive Plan

The Company’s unallocated awards were approved with 8,710,347 (77.82%) votes cast in favour and 2,482,481 (22.18%) votes cast against.

4.   Reapproval of Company’s Shareholder Rights Plan

The Company’s shareholder rights plan was approved with 10,572,490 (94.46%) votes cast in favour and 620,338 (5.54%) votes cast against.

Final voting results on all matters voted on at the meeting will be filed under Haivision’s profile on SEDAR+ at www.sedarplus.ca.

About Haivision

Haivision is a leading global provider of mission-critical, real-time video streaming and visual collaboration solutions. Our connected cloud and intelligent edge technologies enable organizations globally to engage audiences, enhance collaboration, and support decision making. We provide high quality, low latency, secure, and reliable live video at a global scale. Haivision open sourced its award-winning SRT low latency video streaming protocol and founded the SRT Alliance to support its adoption. Awarded four Emmys® for Technology and Engineering from the National Academy of Television Arts and Sciences, Haivision continues to fuel the future of IP video transformation. Founded in 2004, Haivision is headquartered in Montreal and Chicago with offices, sales, and support located throughout the Americas, Europe, and Asia. Learn more at haivision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haivision-announces-voting-results-from-2026-annual-meeting-of-shareholders-302752318.html

SOURCE Haivision Systems Inc.

Continue Reading

Trending